PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Andreas D. HartkopfDepartment of Women's Health, University of Tübingen, Tübingen, Germany, Heidelberg, GermanyFlorin‐Andrei TaranDepartment of Women's Health, University of Tübingen, Tübingen, Germany, Heidelberg, GermanyMarkus WallwienerDepartment of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, GermanyChristina B. WalterDepartment of Women's Health, University of Tübingen, Tübingen, Germany, Heidelberg, GermanyBernhard KrämerDepartment of Women's Health, University of Tübingen, Tübingen, Germany, Heidelberg, GermanyEva‐Maria GrischkeDepartment of Women's Health, University of Tübingen, Tübingen, Germany, Heidelberg, GermanySara Y. BruckerDepartment of Women's Health, University of Tübingen, Tübingen, Germany, Heidelberg, Germany
2016en
ABI
Аннотация
Immune checkpoint inhibition represents a major recent breakthrough in the treatment of malignant diseases including breast cancer. Blocking the programmed death receptor-1 (PD-1) and its ligand, PD-L1, has shown impressive antitumor activity and may lead to durable long-term disease control, especially in the triple-negative subtypes of breast cancer (TNBC). Although immune checkpoint blockade is generally well tolerated, specific immune-related adverse events (irAEs) may occur. This review summarizes the clinical efficacy, perspectives, and future challenges of using PD-1/PD-L1-directed antibodies in the treatment of breast cancer.
Перевод пока недоступен
Идентификаторы
Цитирования и источники
Цитирований: 3Использованных источников: 0